Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Dataset ID

JGAD000116

Type of data
Array CGH
NGS (WGS)
NGS (Target Capture)
Access criteria
Controlled-access (Type I)
Total data volume
194 GB
File formats
  • FASTQ
Research
hum0085
Date published
2020-09-28
Date modified
2026-09-15
DDBJ Search
JGAD000116 (opens in a new tab)
JGA Study
JGAS000108 (opens in a new tab)

Unrestricted-access files linked to this dataset

Download the URL list
FileLabelSizeCopy URL
hum0085_table1.xlsxTable 114.4 KB
hum0085_table2.xlsxTable 29.5 KB
hum0085_table3.xlsxTable 311.0 KB

Analysis method

アレイ CGH

Materials and participants
MMs (ICD10: D48): total 32 cases
- Japanese: 9 cases (tumors and peripheral blood cells)
- American: 21 cases (tumors and peripheral blood cells), 2 cases (tumors only)
  • Health status
    Mixed
  • Subject count
    32 (Individual)
  • Population
    American, Japanese
Disease
MMs (D48)
Sample description
gDNA from MM tumors and reference peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Mixed
Sample provider
N/A
Experimental method
Array CGH
Target
251 refseq genes on chr3p21 (Table 1)
Reagent kit
Agilent DNA Labeling Kit
Platform
Agilent SurePrint G3 8x60K CGH Custom Microarray
QC and filtering
For the aberration filter, the minimum number of probes in regions was set to three and the minimum absolute average log-ratio of region was set to each array.
Analysis method
Data analysis was performed using Agilent CytoGenomics 3.0.5.1. Normalization parameters were set on the GC correction (window size = 2 kb) and diploid peak centralization; the aberration detection was using algorithm ADM-2.
Variant count
Control grid: 3886
Standardized probe group: 1262
Repeated probe group: 5000
Phenotype data
Included
Data use policy
Cancer research only (JGAP000008)
NBDC data sharing policy (JGAP000001)

WGS

Materials and participants
MMs (ICD10: D48): 1 case (Japanese)
  • Health status
    Affected
  • Subject count
    1 (Individual)
  • Population
    Japanese
Disease
MMs (D48)
Sample description
gDNA from MM tumors and reference peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Mixed
Sample provider
N/A
Experimental method
WGS
Target
N/A
Reagent kit
TruSeq DNA Sample Prep Kit
Fragmentation
Ultrasonic fragmentation (Covaris)
Platform
Illumina HiSeq X
Read type
Paired-end
Read length
150 bp
Data use policy
Cancer research only (JGAP000008)
NBDC data sharing policy (JGAP000001)

Targeted DNA sequencing

Materials and participants
MMs (ICD10: D48): total 31 cases
- Japanese: 8 cases (tumors and peripheral blood cells)
- American: 21 cases (tumors and peripheral blood cells), 2 cases (tumors only)
  • Health status
    Affected
  • Subject count
    31 (Individual)
  • Population
    American, Japanese
Disease
MMs (D48)
Sample description
gDNA from MM tumors and reference peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Mixed
Sample provider
N/A
Experimental method
Targeted DNA sequencing
Target
67 genes which were reported as candidates for MM development (chromatin remodeling, histone modification,transcription factor, TP53, CDKN2A, NF2, Table 2)
Reagent kit
HaloPlex Target Enrichment
Fragmentation
Enzymatic fragmentation
Platform
Illumina MiSeq
Read type
Paired-end
Read length
150 bp
Phenotype data
Included
Data use policy
Cancer research only (JGAP000008)
NBDC data sharing policy (JGAP000001)

WES

Materials and participants
familial MMs (ICD10: D48): 2 cases (American)
  • Health status
    Affected
  • Subject count
    2 (Individual)
  • Population
    American
Disease
familial MMs (D48)
Sample description
gDNA from peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Sample provider
N/A
Experimental method
WES
Target
N/A
Reagent kit
SureSelect Human All Exon V4
Fragmentation
Ultrasonic fragmentation (Covaris)
Platform
Illumina HiSeq 4000
Read type
Paired-end
Read length
100 bp
Phenotype data
Included
Data use policy
Cancer research only (JGAP000008)
NBDC data sharing policy (JGAP000001)

Targeted DNA sequencing

Materials and participants
familial MMs (ICD10: D48): 38 cases (American)
- Agilent Haloplex Target Enrichment & Illumina Truseq Custom Amplicon: 25 cases
- Agilent Haloplex Target Enrichment only: 13 cases
  • Health status
    Affected
  • Subject count
    38 (Individual)
  • Population
    American
Disease
familial MMs (D48)
Sample description
gDNA from peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Sample provider
N/A
Experimental method
Targeted DNA sequencing
Target
Agilent Haloplex Target Enrichment: 69 genes (Table 3)
Illumina Truseq Custom Amplicon: 68 genes (Table 3)
Reagent kit
HaloPlex Target Enrichment
TruSeq Custom Amplicon
Fragmentation
Agilent Haloplex Target Enrichment: Enzymatic fragmentation
Illumina Truseq Custom Amplicon: PCR
Platform
Illumina MiSeq
Read type
Paired-end
Read length
Agilent Haloplex Target Enrichment: 150 bp
Illumina Truseq Custom Amplicon: 250 bp
Data use policy
Cancer research only (JGAP000008)
NBDC data sharing policy (JGAP000001)